341 related articles for article (PubMed ID: 31582381)
21. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
[TBL] [Abstract][Full Text] [Related]
22. MITF Modulates Therapeutic Resistance through EGFR Signaling.
Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H
J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707
[TBL] [Abstract][Full Text] [Related]
23. Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas.
Vachtenheim J; Novotná H
Cell Mol Biol (Noisy-le-grand); 1999 Nov; 45(7):1075-82. PubMed ID: 10644012
[TBL] [Abstract][Full Text] [Related]
24. An iterative genetic and dynamical modelling approach identifies novel features of the gene regulatory network underlying melanocyte development.
Greenhill ER; Rocco A; Vibert L; Nikaido M; Kelsh RN
PLoS Genet; 2011 Sep; 7(9):e1002265. PubMed ID: 21909283
[TBL] [Abstract][Full Text] [Related]
25. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas.
Dynek JN; Chan SM; Liu J; Zha J; Fairbrother WJ; Vucic D
Cancer Res; 2008 May; 68(9):3124-32. PubMed ID: 18451137
[TBL] [Abstract][Full Text] [Related]
26. MITF in melanoma: mechanisms behind its expression and activity.
Hartman ML; Czyz M
Cell Mol Life Sci; 2015 Apr; 72(7):1249-60. PubMed ID: 25433395
[TBL] [Abstract][Full Text] [Related]
27. Chromatin remodellers Brg1 and Bptf are required for normal gene expression and progression of oncogenic Braf-driven mouse melanoma.
Laurette P; Coassolo S; Davidson G; Michel I; Gambi G; Yao W; Sohier P; Li M; Mengus G; Larue L; Davidson I
Cell Death Differ; 2020 Jan; 27(1):29-43. PubMed ID: 31065107
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
[TBL] [Abstract][Full Text] [Related]
29. Trametinib-Resistant Melanoma Cells Displaying MITF
Koziej P; Kluszczynska K; Hartman ML; Czyz M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175614
[TBL] [Abstract][Full Text] [Related]
30. RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.
Kunz M; Löffler-Wirth H; Dannemann M; Willscher E; Doose G; Kelso J; Kottek T; Nickel B; Hopp L; Landsberg J; Hoffmann S; Tüting T; Zigrino P; Mauch C; Utikal J; Ziemer M; Schulze HJ; Hölzel M; Roesch A; Kneitz S; Meierjohann S; Bosserhoff A; Binder H; Schartl M
Oncogene; 2018 Nov; 37(47):6136-6151. PubMed ID: 29995873
[TBL] [Abstract][Full Text] [Related]
31. A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma.
Girard CA; Lecacheur M; Ben Jouira R; Berestjuk I; Diazzi S; Prod'homme V; Mallavialle A; Larbret F; Gesson M; Schaub S; Pisano S; Audebert S; Mari B; Gaggioli C; Leucci E; Marine JC; Deckert M; Tartare-Deckert S
Cancer Res; 2020 May; 80(10):1927-1941. PubMed ID: 32179513
[TBL] [Abstract][Full Text] [Related]
32. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor.
Widlund HR; Horstmann MA; Price ER; Cui J; Lessnick SL; Wu M; He X; Fisher DE
J Cell Biol; 2002 Sep; 158(6):1079-87. PubMed ID: 12235125
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators.
Vachtenheim J; Sestáková B; Tuhácková Z
Pigment Cell Res; 2007 Feb; 20(1):41-51. PubMed ID: 17250547
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.
Laugier F; Delyon J; André J; Bensussan A; Dumaz N
Oncogene; 2016 Sep; 35(38):5070-7. PubMed ID: 26973244
[TBL] [Abstract][Full Text] [Related]
35. A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.
Choi J; Xu M; Makowski MM; Zhang T; Law MH; Kovacs MA; Granzhan A; Kim WJ; Parikh H; Gartside M; Trent JM; Teulade-Fichou MP; Iles MM; Newton-Bishop JA; Bishop DT; MacGregor S; Hayward NK; Vermeulen M; Brown KM
Nat Genet; 2017 Sep; 49(9):1326-1335. PubMed ID: 28759004
[TBL] [Abstract][Full Text] [Related]
36. Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
Liu X; Li Z; Li M; Chai J; He S; Wu J; Xu J
Oncol Rep; 2020 Jul; 44(1):360-370. PubMed ID: 32319656
[TBL] [Abstract][Full Text] [Related]
37. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.
Du J; Miller AJ; Widlund HR; Horstmann MA; Ramaswamy S; Fisher DE
Am J Pathol; 2003 Jul; 163(1):333-43. PubMed ID: 12819038
[TBL] [Abstract][Full Text] [Related]
38. STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway.
Swoboda A; Soukup R; Eckel O; Kinslechner K; Wingelhofer B; Schörghofer D; Sternberg C; Pham HTT; Vallianou M; Horvath J; Stoiber D; Kenner L; Larue L; Poli V; Beermann F; Yokota T; Kubicek S; Krausgruber T; Rendeiro AF; Bock C; Zenz R; Kovacic B; Aberger F; Hengstschläger M; Petzelbauer P; Mikula M; Moriggl R
Oncogene; 2021 Feb; 40(6):1091-1105. PubMed ID: 33323974
[TBL] [Abstract][Full Text] [Related]
39. MITF: master regulator of melanocyte development and melanoma oncogene.
Levy C; Khaled M; Fisher DE
Trends Mol Med; 2006 Sep; 12(9):406-14. PubMed ID: 16899407
[TBL] [Abstract][Full Text] [Related]
40. The impact of MITF on melanoma development: news from bench and bedside.
Roider EM; Fisher DE
J Invest Dermatol; 2014 Jan; 134(1):16-17. PubMed ID: 24352080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
